Skip to content
PeptideAgent

Peptides for chronic kidney disease: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Semaglutide is the only peptide with a dedicated kidney outcome trial: in FLOW, semaglutide 1 mg weekly lowered the risk of major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, and FDA added a kidney indication to Ozempic in January 2025. No research peptide has human kidney outcome data.

Evidence: Strongest: Human RCT evidence2 peptides gradedVerified: Verified Sep 27, 2026

Do peptides help with chronic kidney disease?

2 peptides are graded for chronic kidney disease on this page. The strongest grade is human RCT evidence, for semaglutide and liraglutide. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for chronic kidney disease?

Control blood pressure and glucose; an ACE inhibitor or ARB at the maximum tolerated dose when albuminuria is present; an SGLT2 inhibitor for most patients with eGFR of 20 or higher; finerenone or a GLP-1 receptor agonist with kidney benefit in type 2 diabetes; statin therapy; avoid nephrotoxic drugs; nephrology referral for advanced or rapidly progressing disease.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for chronic kidney disease?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Chronic kidney disease with evidence grades
PeptideEvidence for this useNote
SemaglutideEvidence: Human RCT evidenceFLOW (n = 3,533) stopped early for efficacy with a 24% lower risk of kidney failure, sustained eGFR decline, or kidney or cardiovascular death; Ozempic is FDA labeled for this use in type 2 diabetes. [5]
LiraglutideEvidence: Human RCT evidenceKidney outcomes were a secondary endpoint in LEADER, where fewer nephropathy events occurred, driven mainly by less new onset macroalbuminuria; not labeled for kidney protection. [2] [6]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for chronic kidney disease?

Semaglutide and liraglutide have the strongest evidence among the peptides graded here, at human RCT evidence. Semaglutide: FLOW (n = 3,533) stopped early for efficacy with a 24% lower risk of kidney failure, sustained eGFR decline, or kidney or cardiovascular death; Ozempic is FDA labeled for this use in type 2 diabetes. Liraglutide: Kidney outcomes were a secondary endpoint in LEADER, where fewer nephropathy events occurred, driven mainly by less new onset macroalbuminuria; not labeled for kidney protection. [2] [5] [6]

Is any peptide FDA approved for chronic kidney disease?

Semaglutide and liraglutide are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to chronic kidney disease. [2] [5] [6] [7]

Has any peptide been tested in a randomized trial for chronic kidney disease?

Yes, for semaglutide and liraglutide. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [5] [6]

Sources

  1. [1]Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024 (FLOW)PubMed 38785209, 2024
  2. [2]Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)PubMed 27295427, 2016
  3. [3]KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024PubMed 38490803, 2024
  4. [4]FDA prescribing information for Ozempic (semaglutide) injection, via DailyMedFDA, 2025
  5. [5]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA, 2025
  6. [6]FDA prescribing information for Saxenda (liraglutide) injection, via DailyMedFDA, 2025
  7. [7]Drugs@FDA: FDA-approved drugs databaseFDA